Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
作者机构：Division of ImmunologyLCMNGermans Trias i Pujol University Hospital and Research InstituteBarcelonaSpain Department of Cellular BiologyPhysiology and ImmunologyUniversitat Autònoma de BarcelonaBellaterraSpain Multiple Sclerosis UnitDepartment of NeurosciencesGermans Trias i Pujol University HospitalBarcelonaSpain Department of MedicineUniversitat Autònoma de BarcelonaBellaterraSpain View author publications Department of ImmunologyInstitute for Biological Research“Siniša Stanković”-National Institute of Republic of SerbiaUniversity of BelgradeBelgradeSerbia Department of Medical ImmunologyMedical University of GdańskGdańskPoland Poltreg S.A.GdańskPoland Department of Anaesthesiology&Intensive CareMedical University of GdańskGdańskPoland
出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)
年 卷 期：2021年第18卷第6期
页 面：1353-1374页
核心收录：
学科分类：1002[医学-临床医学] 1010[医学-医学技术（可授医学、理学学位）] 100215[医学-康复医学与理疗学] 10[医学]
基 金：funding from the European Union's Horizon 2020 research and innovation program under grant agreement 779316(RESTORE) the support of project PI17/01521 and PI20/01313,integrated in the Plan Nacional de I+D+1 and cosupported by the ISCIII-Subdireccidn General de Evaluacion and the Fondo Europeo de Desarrollo Regional(FEDER) and the support of National Centre for Research and Development,Poland(grant n°STRATEGMED1/233368/1/NCBR/2014).MJ.M.is beneficiary of a Sara Borrell contract from the ISCIII and the FEDER.N.D.and D.M.are supported by MPNTR Republika Srbija,grant n°451-03-68/2020-14/200007
主 题：multiple sclerosis cell-based therapy tolerance neuroprotection autoimmunity
摘 要：Multiple sclerosis(MS)is a leading cause of chronic neurological disability in young to middle-aged adults,affecting~2.5 million people ***,most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs,but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse ***,there is an urgent need for the development of next-generation treatments that,alone or in combination,stop the undesired autoimmune response and contribute to the restoration of *** review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients(tolerogenic dendritic cells,regulatory T cells,mesenchymal stem cells,and vaccination with T cells).Data collected from preclinical studies performed in the experimental autoimmune encephalomyelitis(EAE)model of MS in animals,in vitro cultures of cells from MS patients and the initial results of phase I/II clinical trials are analyzed to better understand which parameters are relevant for obtaining an efficient cell-based therapy for MS.
维普期刊数据库